ProfileGDS5678 / 1433834_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 90% 90% 89% 89% 91% 90% 90% 90% 90% 89% 90% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1380190
GSM967853U87-EV human glioblastoma xenograft - Control 27.3419790
GSM967854U87-EV human glioblastoma xenograft - Control 37.1644590
GSM967855U87-EV human glioblastoma xenograft - Control 47.4512490
GSM967856U87-EV human glioblastoma xenograft - Control 57.049289
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8760189
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.1599191
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1240690
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1120790
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1535390
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.1110390
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1589789
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.2877590
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1641590